rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

Table 1 p53 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	11.83 ± 1.02eb	8.67 ± 1.35eb	6.36 ± 1.62eb
rAd-p53	5 × 106	0	36.65 ± 1.04ca	25.13 ± 2.73ca	21.26 ± 1.07ca
	5 × 107	0	40.32 ± 1.03ca	32.45 ± 2.35ca	25.35 ± 1.28ca
	5 × 108	0	48.86 ± 1.26ca	38.25 ± 2.16ca	29.67 ± 1.31ca
	5 × 109	0	60.38 ± 1.14ca	49.37 ± 1.07ca	33.25 ± 2.05ca
rAd-p53 + OXA	5 × 106	3.2	37.23 ± 1.07eca	26.54 ± 1.53eca	22.17 ± 1.13eca
	5 × 107	3.2	39.83 ± 1.32eca	34.17 ± 1.26eca	24.83 ± 1.07eca
	5 × 108	3.2	49.03 ± 1.26eca	40.28 ± 1.43eca	30.45 ± 1.32eca
	5 × 109	3.2	61.54 ± 1.18eca	50.37 ± 1.27eca	35.21 ± 2.1eca
Control	0	0	12.55 ± 1.15	8.23 ± 1.13	6.15 ± 1.36

^aP < 0.05 vs control,

^bP > 0.05 vs control;

^cP > 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.